Only in Titles

Search results for: L Cystine CAS Number [56 89 3]

paperclip

#32198276   2020/03/20 To Up

Use of Human Induced Pluripotent Stem Cells and Kidney Organoids To Develop a Cysteamine/mTOR Inhibition Combination Therapy for Cystinosis.

Mutations in -a gene encoding the cystine transporter cystinosin-cause the rare, autosomal, recessive, lysosomal-storage disease cystinosis. Research has also implicated cystinosin in modulating the mTORC1 pathway, which serves as a core regulator of cellular metabolism, proliferation, survival, and autophagy. In its severest form, cystinosis is characterized by cystine accumulation, renal proximal tubule dysfunction, and kidney failure. Because treatment with the cystine-depleting drug cysteamine only slows disease progression, there is an urgent need for better treatments.
Jennifer A Hollywood, Aneta Przepiorski, Randall F D'Souza, Sreevalsan Sreebhavan, Ernst J Wolvetang, Patrick T Harrison, Alan J Davidson, Teresa M Holm

2604 related Products with: Use of Human Induced Pluripotent Stem Cells and Kidney Organoids To Develop a Cysteamine/mTOR Inhibition Combination Therapy for Cystinosis.

100ul 100ul200 1 kit(96 Wells)100 5 x 50 ug25 20 ug 100ul 100ul1001.00 flask

Related Pathways